English

ema.europa.eu

Friday, Jul 11

13

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 – 10 July 2025

www.ema.europa.eu

Vaccine to be used only when there is a significant chikungunya risk and after careful consideration of the benefits and risks EMA’s safety committee (PRAC) has completed its…, Agenda Agenda of the PRAC meeting 7-10 July 2025DraftReference…

11

Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted

www.ema.europa.eu

EMA’s safety committee (PRAC) has completed its review of Ixchiq (a live attenuated chikungunya vaccine), following reports of serious side effects.The previous temporary…

Friday, Jul 4

14

Strengthening supply chain of anti-D immunoglobulins

www.ema.europa.eu

EMA and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), have issued…

Friday, Jun 20

18

EMA starts review of sodium oxybate in alcohol dependence

www.ema.europa.eu

EMA’s human medicines committee (CHMP) has started a review of medicines containing sodium oxybate used in people with alcohol dependency to treat alcohol withdrawal syndrome and…, Contact point Media enquiriesTel. +31 (0)88 781 8427E-mail…

13

New stem cell therapy to treat patients with blood cancers

www.ema.europa.eu

EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Zemcelpro (dorocubicel / unexpanded umbilical cord cells) to treat adults…

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 June 2025

www.ema.europa.eu

13 new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended 13 medicines for approval at its June 2025 meeting.The committee recommended granting a…, CHMP statistics Key figures from the June 2025 CHMP…

11

First treatment against liver scarring caused by a type of ‘fatty liver disease’

www.ema.europa.eu

EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Rezdiffra (resmeritom) for the treatment of adults with noncirrhotic metabolic…

Friday, Jun 13

17

EMA Management Board: highlights of June 2025 meeting

www.ema.europa.eu

Management Board meets the African Medicines Agency Governing BoardThe Management Board welcomed the African Medicines Agency (AMA) Governing Board and heads of African national…

First vaccine against swine dysentery disease recommended for approval

www.ema.europa.eu

EMA has issued a positive opinion for the approval of a vaccine named Biobhyo, indicated to protect pigs from swine dysentery, a disease that causes dysenteric diarrhoea in pigs.…

16

PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy

www.ema.europa.eu

This news announcement was revised on 13 June 2025 to delete the reference to the European Commission issuing a legally binding decision on the procedure., EMA’s safety committee (PRAC) has concluded its review of medicines containing…

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 10-12 June 2025

www.ema.europa.eu

The Committee re-elected Dr Frida Hasslung Wikström from Sweden as its Vice-chair for a further 3-year mandate.CVMP opinions on veterinary medicinal productsThe Committee adopted…

Tuesday, Jun 10

15

2024 annual report is published

www.ema.europa.eu

EMA’s annual report 2024 published today gives insights into the Agency’s strategic priorities and contributions to public and animal health in the European Union (EU).The digital…

Friday, Jun 6

13

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025

www.ema.europa.eu

PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicinesTreatment with semaglutide should be stopped if NAION occursEMA’s safety committee (PRAC) has…, Agenda Agenda of the PRAC meeting 2-5 June…

Thursday, Jun 5

15

EMA closed 9 June

www.ema.europa.eu

The European Medicines Agency (EMA) is closed from 18:00 on Friday 6 June 2025 until 08:30 on Tuesday 10 June 2025.The product emergency hotline is available outside working hours…

Wednesday, Jun 4

14

New guideline on inclusion of pregnant and breastfeeding individuals in clinical trials

www.ema.europa.eu

EMA has released for public consultation a new guideline providing recommendations on how to include and/or retain pregnant and breastfeeding people in clinical trials. The goal…

Wednesday, May 28

10

EMA closed 29-30 May

www.ema.europa.eu

The European Medicines Agency (EMA) is closed from 18:00 on Wednesday 28 May 2025 until 08:30 on Monday 2 June 2025.The product emergency hotline is available outside working…

Friday, May 23

14

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2025

www.ema.europa.eu

Ten new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended ten medicines for approval at its May 2025 meeting.The committee recommended granting…, Positive recommendations on new medicines , Aucatzyl…

13

Changes to the use of antibiotic azithromycin

www.ema.europa.eu

EMA’s human medicines committee (CHMP) has recommended several changes to the way the antibiotic azithromycin is used in the EU, including the removal of certain indications.…

EMA starts review of ipidacrine-containing medicines

www.ema.europa.eu

EMA’s human medicines committee (CHMP) has started a review of medicines containing ipidacrine. These medicines have been authorised in several EU countries through national…

New treatment for adults with acute lymphoblastic leukaemia

www.ema.europa.eu

EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Aucatzyl (obecabtagene autoleucel) to treat adults from 26 years of age with…

Friday, May 16

16

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 13-15 May 2025

www.ema.europa.eu

The Committee re-elected Johan Schefferlie from the Netherlands as its Chair for a further 3-year mandate.CVMP opinions on veterinary medicinal productsThe Committee adopted by…, Maximum residue limits Lidocaine (Porcine) - Summary opinion…

14

ETF recommends updating COVID-19 vaccines to target new LP.8.1 variant

www.ema.europa.eu

EMA’s Emergency Task Force (ETF) has recommended updating COVID-19 vaccines to target the new SARS-CoV-2 variant LP.8.1 for the 2025/2026 vaccination campaign.LP.8.1 differs from…

Thursday, May 8

16

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 May 2025

www.ema.europa.eu

Review of medicines containing finasteride and dutasteride concluded Finasteride and dutasteride tablets: Measures to minimise risk of suicidal thoughtsFollowing an EU-wide…, Agenda Agenda of the PRAC meeting 5-8 May 2025DraftReference…

Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines

www.ema.europa.eu

Following an EU-wide review of available data on finasteride and dutasteride medicines, EMA’s safety committee, PRAC, has confirmed suicidal ideation (suicidal thoughts) as a side…, The product information for finasteride 1 mg tablets will…

Wednesday, May 7

15

Leveraging the power of data for public and animal health

www.ema.europa.eu

EMA and the Heads of Medicines Agencies (HMA) have published a joint workplan "Data and AI in medicines regulation to 2028". It sets out how the European medicines regulatory…, "In view of the technology-driven explosion of data, we need…

EMA starts review of Ixchiq (live attenuated chikungunya vaccine)

www.ema.europa.eu

EMA’s safety committee (PRAC) has started a review of Ixchiq (a live attenuated chikungunya vaccine) following reports of serious adverse events in elderly people.Many of the…

14

EMA closed on 9 May

www.ema.europa.eu

The European Medicines Agency's (EMA) office is closed from 18:00 on Thursday 8 May 2025 to 08:30 on Monday 12 May 2025. EMA is hosting its first Open Door Day on Friday…

Tuesday, Apr 29

EMA closed 1 May

www.ema.europa.eu

The European Medicines Agency's (EMA) office is closed from 18:00 on Wednesday 30 April 2025 to 08:30 on Friday 2 May 2025.Outside of working hours and on public holidays, it…

Monday, Apr 28

17

Management Board meeting on possible renewal of Executive Director’s mandate

www.ema.europa.eu

EMA’s Management Board has unanimously recommended the renewal of its Executive Director Emer Cooke’s mandate. This recommendation was given in response to a consultation request…

Friday, Apr 25

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025

www.ema.europa.eu

16 new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended 16 medicines for approval at its April 2025 meeting.The CHMP recommended granting a…, Positive recommendations on new medicines , Alyftrek…